Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 3Phase NA 2Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Plasma cell 2Other hematologic neoplasm 2Gastrointestinal 2Thoracic 1Myeloid 1Gynecologic 1

Conditions

Breast Neoplasms 4Vomiting 3Nausea 2Inflammatory Breast Neoplasms 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 171Docetaxel 164Paclitaxel 160Trastuzumab 152Capecitabine 130Tamoxifen 119Letrozole 105Epirubicin 93Doxorubicin 83Anastrozole 83exemestane 77Fulvestrant 75Carboplatin 64Fluorouracil 63Radiotherapy 61pertuzumab 59Gemcitabine 55Vinorelbine 43Goserelin 39eribulin 36130-nm albumin-bound paclitaxel 36palbociclib 32Bevacizumab 32ribociclib 30Zoledronic Acid 29Lapatinib 29Methotrexate 28Drug Therapy 28Chemotherapy, Adjuvant 28Ado-Trastuzumab Emtansine 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Aprepitant × Breast × Clear all
NCT02336750 2022-04-20

Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis

Fudan University

Phase 3 Completed
212 enrolled
Breast

Breast Neoplasms

NCT00092196 2017-05-05

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
820 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

NCT00475085 2015-11-10

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

University of Rochester

Phase 3 Completed
1,021 enrolled 10 charts
Breast

Breast Neoplasms, Nausea, Vomiting, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00869973 2013-01-23

Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients

S. Maria Hospital, Terni

Phase 3 Terminated
580 enrolled
Breast

Breast Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡